Development of an innovative, effective, and safe inhalation drug for the treatment of mucus plugs in cystic fibrosis and COPD

Important results from the project

The project resulted in a clearer business model, a well-developed market and commercialization strategy, and a concrete, executable plan for continued development through completion of Phase 1 clinical trials. Although the project did not secure funding from the EIC Transition program, it established a strong foundation for further progress by increasing regulatory clarity, fostering valuable collaborations, and improving the conditions for future investments and partnerships.

Expected long term effects

The project is expected to help bring new and effective treatments for mucus-related lung diseases to patients with unmet medical needs. Through a mature development program, a strengthened business strategy, and established collaborations, the project creates improved conditions for clinical development, international partnerships, and investment. Overall, it strengthens the company’s long-term competitiveness and contributes to innovation and growth within the Swedish life science sector.

Approach and implementation

The project was implemented with a clear structure based on defined work packages for business development, regulatory strategy, clinical planning, and industrial development. The activities were relevant and well aligned with the project’s objectives and were largely carried out according to schedule. No major external or unforeseen events significantly affected the implementation. Collaboration with external experts and partners contributed to an efficient execution.